default author photo

Lívia Pimenta Bonifácio

University of São Paulo (USP) - Ribeirão Preto Medical School

SCHOLARLY PAPERS

1

DOWNLOADS

108

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Efficacy and Safety of Ixekizumab vs. Low-Dose IL-2 vs. Colchicine vs. Standard of Care on the Treatment of Patients Hospitalized with Moderate to Critical Covid-19: A Pilot Randomized Clinical Trial (STRUCK: Survival Trial Using Cyto kine Inhibitors)

Number of pages: 17 Posted: 28 Apr 2022
Lívia Pimenta Bonifácio, Eduardo Ramacciotti, Leandro Barile Agati, Fernando C. Vilar, Anna Christina Tojal da Silva, Paulo Louzada-Junior, Benedito Antonio Lopes da Fonseca, Hayala Cristina Cavenague de Souza, Caroline Candida Carvalho de Oliveira, Valéria Cristina Resende Aguiar, Carlos Augusto de Aguiar Quadros, Cesar Dusilek, Kenji Itinose, Ricardo Gustavo Zill Risson, Lucas Roberto Rivabem Ferreira, Rogério Aparecido Dedivitis, André Sementilli Cortina, Renato Delascio Lopes, Esper Georges Kallas and Fernando Bellissimo-Rodrigues
University of São Paulo (USP) - Ribeirão Preto Medical School, Science Valley Research Institute, Science Valley Research Institute, University of São Paulo (USP) - Ribeirão Preto Medical School, University of São Paulo (USP) - Ribeirão Preto Medical School, University of São Paulo (USP) - Ribeirão Preto Medical School, University of São Paulo (USP) - Ribeirão Preto Medical School, University of São Paulo (USP) - Ribeirão Preto Medical School, Science Valley Research Institute, Science Valley Research Institute, Hospital e Maternidade Christóvão da Gama, Hospital do Rocio, Hospital do Rocio, Hospital do Rocio, Hospital do Rocio, Irmandade Santa Casa de Misericórdia de Porto Alegre, Irmandade Santa Casa de Misericórdia de Porto Alegre, Brazilian Clinical Research Institute, University of São Paulo (USP) - Hospital das Clinicas HCFMUSP and University of São Paulo (USP) - Ribeirão Preto Medical School
Downloads 108 (649,907)

Abstract:

Loading...

Covid-19, SARS-CoV-2, Cytokine storm, Ixekizumab, Interleukin-2, Colchicine